Fabhalta (iptacopan hydrochloride) Copay Card and Patient Assistance Programs

Yes — Fabhalta (iptacopan hydrochloride) has 1 manufacturer-sponsored patient support program including a copay card for eligible commercially-insured patients. Below: what each program covers, exactly what you need to enroll, and direct links to apply.

Last verified: July 10, 2026

Support programs at a glance

ProgramTypeMax benefitWho qualifiesEnroll
Novartis Patient Support — Fabhalta Co-Pay Plus Copay card + Patient assistance / free drug Up to $20,000/year Commercial Only Enroll →

What you need to enroll

What you need to enroll — Novartis Patient Support — Fabhalta Co-Pay Plus

Submitted via: Online form. No periodic renewal required once enrolled.

  • Sign up after your provider prescribes FABHALTA (online, by phone, or through your provider's office) — provided by Patient

Frequently asked questions

Is there a copay card for Fabhalta?

Yes. Eligible commercially insured patients may pay as little as $0 per year; up to $20,000 annual co-pay benefit plus up to $1,000 for qualifying vaccination costs

What if I'm uninsured or can't afford Fabhalta?

Novartis patient assistance for qualifying uninsured/underinsured patients; contact Novartis Patient Support for details

How do I enroll in a Fabhalta patient support program?

Submission is via online form. See the "What you need to enroll" checklist above for the exact documents and who provides each one.

Is this information from Novartis Pharmaceuticals Corporation official?

Program details are sourced from Novartis Pharmaceuticals Corporation's own published program pages and verified on the date shown above. This site is an independent directory, not affiliated with the manufacturer — always confirm current terms directly with the program before relying on them.

Sources

This is an independent resource, not affiliated with, endorsed by, or funded by Novartis Pharmaceuticals Corporation. Program terms change — always verify current details directly with the program before enrolling. View this drug in the full searchable directory →